… A subsequent open-label extension study involving 39 patients … , with some patients
maintaining long-term (up to 2 years) … studies in patients with chronic cancer-related or …

… reports safety data from RCTs and related open-label studies … were considered to be
cancer-related and not related to … capsules, dronabinol, nabilone and THC/CBD oral capsules …

… An open-label extension study to investigate the long-term safety and tolerability of THC/CBD
oromucosal spray and … cancer-related pain refractory to strong opioid analgesics. J …

… cannabis to patients suffering from cancer-related pains. Only clinical … open-label extension
study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray …

… or second-line therapy or for long-term treatment [1]. Nevertheless, … This was a retrospective,
open-label, parallel-group, flexible-… of patients with active cancer and/or cancer-related pain; …

… goals and tolerance. Dispensaries provided records of all … with a specific THC/CBD dose.
The mean, median, and range at … in non-cancer-related pain [16], we analyzed pain and total …

… is a cannabis extract containing fixed doses of THC-CBD, THC or … , oral spray) in 43 patients
with cancer-related pain and … Most non-randomized trials were single-arm, open-label with …

… Up to 40% of the patients with cancer-related pain have neuropathic … A long-term observational
study conducted in Israel … (producing effective pain management with tolerable adverse …

… pain), whereas one was an open‐label trial in 174 people that … [THC], cannabidiol [CBD],
THC:CBD combinations, THC … with cancer‐related pain,272 and opioid‐related deaths in …

… its effectiveness to alleviate cancer-related pain [79]. This study was open-label with a self-…
In patients with pain due to spinal cord injury, oral THC/CBD self-administered up to 130 mg/…